

Author's Accepted Manuscript



Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment

Peter Chang , Meredith M. Regan , Montserrat Ferrer , Ferran Guedea , Dattatraya Patil , John T. Wei , Larry A. Hembroff , Jeff M. Michalski , Chris S. Saigal , Mark S. Litwin , Daniel A. Hamstra , Irving D. Kaplan , Jay P. Ciezki , Eric A. Klein , Adam S. Kibel , Howard M. Sandler , Rodney L. Dunn , Catrina M. Crociani , Martin G. Sanda

PII: S0022-5347(16)31198-3
DOI: [10.1016/j.juro.2016.08.101](https://doi.org/10.1016/j.juro.2016.08.101)
Reference: JURO 13982

To appear in: *The Journal of Urology*
Accepted Date: 19 August 2016

Please cite this article as: Chang P, Regan MM, Ferrer M, Guedea F, Patil D, Wei JT, Hembroff LA, Michalski JM, Saigal CS, Litwin MS, Hamstra DA, Kaplan ID, Ciezki JP, Klein EA, Kibel AS, Sandler HM, Dunn RL, Crociani CM, Sanda MG, and the PROST-QA Consortium, Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment, *The Journal of Urology*® (2016), doi: 10.1016/j.juro.2016.08.101.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

Embargo Policy

All article content is under embargo until uncorrected proof of the article becomes available online.

We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date. Questions regarding embargo should be directed to jumedia@elsevier.com.

1. TITLE PAGE**Title: Relief of Urinary Symptom Burden after Primary Prostate Cancer Treatment****Authors: Peter Chang, MD, MPH; Meredith M. Regan, ScD; Montserrat Ferrer, MD, MPH; Ferran Guedea, MD, PhD; Dattatraya Patil, MS, MBBS; John T. Wei, MD, MS; Larry A. Hembroff, PhD; Jeff M. Michalski, MD, MBA; Chris S. Saigal, MD, MPH; Mark S. Litwin, MD, MPH; Daniel A. Hamstra, MD, PhD; Irving D. Kaplan, MD; Jay P. Ciezki, MD; Eric A. Klein, MD; Adam S. Kibel, MD; Howard M. Sandler, MD; Rodney L. Dunn, MS; Catrina M. Crociani, MPH; Martin G. Sanda, MD; and the PROST-QA Consortium**

From the Department of Surgery (P.C., C.M.C.), and the Department of Radiation Oncology (I.D.K), Beth Israel Deaconess Medical Center and Harvard Medical School; the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Harvard Medical School (M.M.R.), Boston; the Health Services Research Unit (M.F.), Hospital del Mar Research Institute, Barcelona, Spain; the Department of Radiation Oncology (F.G.), Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Spain; the Department of Urology (J.T.W., R.L.D.), University of Michigan, Ann Arbor; the Office for Survey Research, Institute for Public Policy and Social Research (L.A.H.), Michigan State University, East Lansing; the Department of Radiation Oncology (J.M.M.), Washington University, St. Louis; the Departments of Urology (M.S.L., C.S.S.) and Health Policy and Management (M.S.L.), UCLA Center for Health Sciences, Los Angeles; Texas Center for Proton Therapy (D.A.H.), Irving, TX; the Departments of Radiation Oncology (J.P.C.) and the Glickman Urological and Kidney Institute (E.A.K.), Cleveland Clinic, Cleveland; the Division of Urology (A.S.K.), Brigham and Women's Hospital and Harvard Medical School; Department of Radiation Oncology (H.M.S.), Cedars-Sinai Medical Center; the Department of Urology (M.G.S, D.P.), Emory University School of Medicine, Atlanta.

Corresponding author:**Peter Chang, M.D., M.P.H.****Director, Prostate Cancer Care Center****Beth Israel Deaconess Medical Center; Harvard Medical School****330 Brookline Avenue, Rabb 440****Boston, MA 02215****Phone: 617-667-4075****Fax: 617-667-7292****Email: pchang@bidmc.harvard.edu****Funding:**

PROST-QA Consortium Funded by National Institutes of Health Grants R01 CA95662, RC1 CA146596, and RC1 EB011001. The Multicentric Spanish Group of Clinically Localized Prostate Cancer was supported by a grant from Instituto de Salud Carlos III FEDER: Fondo Europeo de Desarrollo Regional (PI13/00412). Dr. Chang is supported by a Urology Care Foundation Research Scholar Award and the Martin and Diane Trust Career Development Chair in Surgery.

Work presented at the American Urological Association Annual Meeting in 5/2014 at Orlando, FL.

Text word limit: 2500 words**Current text word count:** 2498 words**Abstract word limit:** 250 words**Current abstract word count:** 250 words

Download English Version:

<https://daneshyari.com/en/article/5687050>

Download Persian Version:

<https://daneshyari.com/article/5687050>

[Daneshyari.com](https://daneshyari.com)